Has Marideli Scanlan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $446,036 in general payments to Marideli Scanlan, MD across 1,007 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marideli Scanlan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marideli Scanlan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marideli Scanlan, MD

Endocrinology, Diabetes & Metabolism · Marrero, LANPI 1205027349

Payments from drug & device makers

$446,036in general payments, 2019–2025

Across 1,007 payments — averaging $442.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$201K
Lilly USA, LLC$127K
Dexcom, Inc.$67K
Boehringer Ingelheim$26K
AstraZeneca$17K
Ascendis Pharma Endocrinology Inc$2K
plus $6K from 37 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	334	$200,674
Lilly USA, LLC	240	$127,420
Dexcom, Inc.	88	$66,927
Boehringer Ingelheim	56	$26,091
AstraZeneca(2 entities)	45	$17,460
Ascendis Pharma Endocrinology Inc	8	$1,871
Amgen(2 entities)	31	$780
BETA Bionics, Inc.	6	$660
Sanofi-aventis U.S. LLC	25	$504
Corcept Therapeutics	11	$425
Bayer	11	$296
Abbott	13	$282
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	17	$278
Johnson & Johnson	11	$256
Xeris Pharmaceuticals, Inc.	10	$208
Amarin Pharma, Inc.	7	$175
Medtronic(2 entities)	10	$152
Merck	10	$144
Radius Health, Inc.	6	$118
Tandem Diabetes Care, Inc.	4	$116
AbbVie	6	$115
Pfizer	6	$114
Amneal Pharmaceuticals LLC	6	$99
IBSA Pharma Inc.	6	$98
Regeneron Healthcare Solutions, Inc.	5	$97
Insulet Corporation	4	$89
Esperion Therapeutics, Inc.	5	$82
Valeritas, Inc.	2	$73
Recordati_rare_diseases_inc.	3	$60
Antares Pharma, Inc.	3	$55
Neurocrine Biosciences, Inc.	2	$52
Shire North American Group Inc	3	$51
Theratechnologies Inc.	2	$38
Ironwood Pharmaceuticals, Inc	2	$33
Ultragenyx Pharmaceutical Inc.	1	$23
Halozyme Inc	1	$18
Sequel Med Tech, LLC	1	$18
Novartis	1	$16
Mannkind Corporation	1	$16
Ascensia Diabetes Care US Inc.	1	$15
Lifescan, Inc.	1	$15
BD	1	$12
Cequr Corporation	1	$12

How this compares

$446,036 in reported general payments places this provider in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.

See all endocrinology, diabetes & metabolism providers in Louisiana →

Medicare billing

Part B allowed, 2024

$28,297

Medicare patients

107

Services billed

370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Marrero

Tilak MallikMarrero$78K
Alejandra Riera GonzalezMarrero$7K
Sarah KeslerMarrero$5K
Amy VarugheseMarrero$3K
Tuan Huy TranMetairie$2M
Harold MillerHammond$1.1M
Timothy GilbertBaton Rouge$985K
Justin FontenotLafayette$905K
Vivian FonsecaNew Orleans$700K
Frank GreenwayBaton Rouge$669K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →